US FDA Approves Abbreviated NDA for Heparin Sodium
17 July 2020 - - The U.S. Food and Drug Administration has approved an abbreviated new drug application, or generic, for heparin sodium, the agency said.
This drug is an anti-coagulant to prevent blood clotting.
The FDA said it recognises the increased demand for certain products during the COVID-19 public health emergency and remains deeply committed to facilitating access to medical products to help address critical needs of the American public.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.
The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.